Hypercholesterolemia is one of the principal promoters of the atherosclerotic plaque genesis (Steinberg, ), representing a relevant cardiovascular (CV) risk factor (Mozaffarian et al., ). Therefore, a goal of primary and secondary prevention of CV diseases is the reduction of low‐density lipoprotein (LDL) cholesterol levels (National Cholesterol Education Program [NCEP] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III], ). In this context, the use of statins as lipid‐lowering drugs has been, until now, a key step in reducing the CV risk (Naci et al., ; Taylor, Huffman, & Ebrahim, ); however, a new class of lipid‐lowering drugs that significantly reduce the levels of LDL cholesterol has recently emerged: the inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) (Giugliano & Sabatine, ; Gouni‐Berthold & Berthold, ; Sahebkar, Chew, & Watts, ; Sahebkar & Watts, ). PCSK9 is a protein that interacts with the LDL receptor (LDLR) favoring early degradation and preventing recycling. Monoclonal antibodies against PCSK9 increase the hepatic gene expression of LDLR, resulting in a pronounced cholesterol‐lowering effect caused by the LDL internalization processes.However, despite the enthusiasm generated by the efficacy of such drugs in lowering LDL cholesterol (Canevari &
Journal of Neuroscience Research – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud